Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Up 71.6% in February

Jasper Therapeutics, Inc. is a biopharmaceutical company that focuses on developing and commercializing novel therapies for rare genetic diseases. The company's lead product candidate is JTI-180, an oral therapy for the treatment of Duchenne muscular dystrophy (DMD), a rare and progressive muscle disorder that affects boys.

On February 15th, the short interest in Jasper Therapeutics, Inc.'s common stock increased by 71.6% from the January 31st total of 7,400 shares to 12,700 shares. Short interest represents the number of shares that have been borrowed by investors with the intention of selling them in the future.

The increase in short interest could be due to a variety of factors, including negative news about the company or its products, changes in market conditions, or simply a shift in investor sentiment. It is important to note that short interest does not necessarily indicate anything about the underlying value of a company's stock, and it can fluctuate rapidly based on market forces.

As of February 15th, Jasper Therapeutics, Inc.'s common stock had an average daily volume of 21,900 shares. This means that on any given day, approximately 21,900 shares of the company's stock are bought and sold on public exchanges such as NASDAQ.

Overall, while the increase in short interest in Jasper Therapeutics, Inc.'s common stock is worth noting, it is important to approach this information with caution and to consider a range of factors when evaluating the company's prospects.